Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,025.28 +3.91 (+0.38%)
Official Closing Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
News headline image
3 Growth Stocks I'm Loading Up On ↗
Via The Motley Fool
Topics Artificial Intelligence Government
News headline image
5 Revealing Analyst Questions From Eli Lilly’s Q1 Earnings Call
Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging competitive pressures. Management credited the surge in sales to the... 
Via StockStory
Topics Earnings World Trade
News headline image
Why Shares in Novo Nordisk Lost Weight Today ↗
Via The Motley Fool
News headline image
US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows ↗
GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only 8.1% stayed on therapy for three years. 
Via Benzinga
News headline image
Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity ↗
The company just initiated two Phase 3 studies of its weekly under-the-skin shot to stoke weight loss. 
Via Investor's Business Daily
News headline image
What's Going On With Viking Therapeutics Stock On Wednesday? ↗
Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks. 
Via Benzinga
News headline image
Which S&P500 stocks are moving on Wednesday? ↗
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday. 
Via Chartmill
News headline image
Tesla's Robotaxi Rollout ↗
Via The Motley Fool
Topics Stocks
News headline image
7 Space Stocks I'd Buy Without Hesitation ↗
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow ↗
Via The Motley Fool
Topics Government World Trade
News headline image
Eli Lilly’s Newest Obesity Drug Candidate Stirs Wall Street Buzz, But Not Everyone’s Sold ↗
Bimagrumab showed promising fat loss results in a mid-stage trial, but analysts raised concerns about safety and say more data is needed. 
Via Stocktwits
News headline image
Novo's India Move Could Reshape The Weight-Loss Drug War With Eli Lilly ↗
Novo Nordisk launches Wegovy in India, pricing it close to Eli Lilly's Mounjaro, while advancing global regulatory efforts for its GLP-1 portfolio. 
Via Benzinga
News headline image
New AI Rollouts Signal Shift From Hype to Healthcare Reality
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:LLY),(NASDAQ:PLTR),(NYSE:PHG),(NASDAQ:WAY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Hims & Hers CEO Hits Back At Novo Nordisk After Abrupt End Of Collaboration, Alleges Wegovy-Maker Is ‘Misleading The Public’ ↗
HIMS CEO said that the pharma company’s commercial team has been increasingly pressuring the company to control clinical standards and steer patients to Wegovy regardless of whether it is clinically... 
Via Stocktwits
News headline image
Amgen Expands Development Plans For Highly Anticipated Obesity Drug ↗
Amgen is expanding its plans for weight-loss drug, MariTide, with a trio of upcoming Phase 3 studies. 
Via Investor's Business Daily
News headline image
Why Novo Nordisk Stock Is Sinking Today ↗
Via The Motley Fool
Topics Stocks Supply Chain
News headline image
IWF Is a Great Choice for Most, But I Like VUG ETF Better ↗
Via The Motley Fool
Topics ETFs
News headline image
Novo Nordisk's Weight Loss Injection CagriSema Data Sparks Investor Concern ↗
Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals. 
Via Benzinga
News headline image
Eli Lilly's Investigational Oral Pill Shows Weight Loss Benefits With Lingering Side Effect Concerns ↗
Eli Lilly's orforglipron reduced A1C and weight in type 2 diabetes, while weekly insulin efsitora matched daily insulin with fewer side effects. 
Via Benzinga
News headline image
Watch Out, Novo Nordisk & Eli Lilly: Chinese Biotech Steps Into the Ring To Take On Global Weight-Loss Leaders ↗
Sciwind Biosciences is expanding its global footprint with licensing deals and early talks for overseas development, as it eyes a double-digit market share in China's fast-growing obesity drug sector. 
Via Stocktwits
News headline image
Eli Lilly Hits Dual Wins: Orforglipron, Efsitora Meet Phase 3 Goals For Blood Sugar, Weight Loss And Diabetes Care ↗
Efsitora matched or exceeded A1C reductions seen with daily basal insulin across three trials, while orforglipron demonstrated benefits for blood sugar control and weight loss at higher doses. 
Via Stocktwits
News headline image
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts ↗
Via The Motley Fool
News headline image
Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere ↗
The U.S. trade deficit with Ireland has surged as $36 billion in hormone shipments for weight-loss and diabetes drugs were flown in to meet demand and avoid tariffs. 
Via Benzinga
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session. 
Via Chartmill
News headline image
3 'Underdog Stocks' For The Rest Of 2025 ↗
 
Via Benzinga
News headline image
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering ↗
FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research 
Via Benzinga
News headline image
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week ↗
Via The Motley Fool
News headline image
Stay informed with the top movers within the S&P500 index on Friday. ↗
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
News headline image
Friday's session: gap up and gap down stock in the S&P500 index ↗
Let's have a look at what is happening on the US markets on Friday. Below you can find the S&P500 gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Looking At Eli Lilly's Recent Unusual Options Activity ↗
 
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.